Lupin (LUPIN.NS) Stock Price

Lupin Price

NSE·CLOSED
2,300.00INR-63.50 (-2.72 %)
Market closed

Over the last 19 years Lupin grew revenue by 14.4% annually, reaching 227.08 B INR. Earnings per share have grown at 16.1% per year over the last 19 years. For Lupin, the net margin of 14.5% is up versus 8.0% a few years ago. At today's price the dividend yield works out to roughly 0.52%. The payout ratio is around 17% of earnings. The dividend has grown at 3.3% per year over the past 19 years. The consensus 12-month price target for Lupin is 2,397.00 INR, about 4.2% above where the stock trades today. Of 43 analysts, 29 rate the stock a buy — an overall Buy consensus. The stock trades about 22% above its 52-week low.

Lupin stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Lupin over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Lupin stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Lupin's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Lupin Stock Price History
DateLupin Price
8/10/20262,300.00 INR
8/7/20262,363.50 INR
8/6/20262,385.00 INR
8/5/20262,388.00 INR
8/4/20262,397.80 INR
7/31/20262,415.00 INR
7/30/20262,463.80 INR
7/29/20262,447.00 INR
7/28/20262,407.40 INR
7/24/20262,370.50 INR
7/23/20262,397.90 INR
7/22/20262,406.90 INR
7/21/20262,514.80 INR
7/20/20262,478.50 INR
7/17/20262,443.20 INR
7/16/20262,500.50 INR
7/15/20262,493.00 INR
7/14/20262,469.20 INR
7/13/20262,492.60 INR
7/10/20262,496.30 INR
7/9/20262,503.30 INR
7/8/20262,459.00 INR
7/7/20262,490.20 INR
7/6/20262,491.60 INR
7/3/20262,477.40 INR
7/2/20262,399.60 INR
7/1/20262,397.50 INR
6/30/20262,419.00 INR
6/29/20262,409.30 INR
6/25/20262,343.50 INR
6/24/20262,367.60 INR
6/23/20262,357.80 INR
6/22/20262,340.00 INR
6/19/20262,351.60 INR
6/18/20262,327.10 INR
6/17/20262,272.00 INR
6/16/20262,277.80 INR
6/15/20262,279.80 INR
6/12/20262,293.30 INR
6/11/20262,273.30 INR
6/10/20262,274.60 INR
6/9/20262,264.20 INR
6/8/20262,254.50 INR
6/5/20262,267.70 INR
6/4/20262,249.80 INR
6/3/20262,261.20 INR
6/2/20262,249.80 INR
6/1/20262,262.90 INR
5/29/20262,267.70 INR
5/27/20262,276.40 INR
5/26/20262,266.00 INR
5/25/20262,287.20 INR
5/22/20262,281.80 INR
5/21/20262,284.50 INR
5/20/20262,302.30 INR
5/19/20262,287.40 INR
5/18/20262,252.40 INR
5/15/20262,276.20 INR
5/14/20262,258.20 INR
5/13/20262,215.60 INR
5/12/20262,245.40 INR
5/11/20262,255.90 INR
5/8/20262,379.50 INR
5/7/20262,460.10 INR
5/6/20262,442.90 INR
5/5/20262,343.30 INR
5/4/20262,348.80 INR
5/1/20262,305.20 INR
4/30/20262,305.20 INR
4/29/20262,311.40 INR
4/28/20262,302.70 INR
4/27/20262,324.50 INR
4/24/20262,296.10 INR
4/23/20262,341.40 INR
4/22/20262,307.90 INR
4/21/20262,311.50 INR
4/20/20262,328.70 INR
4/17/20262,326.10 INR
4/16/20262,327.00 INR
4/15/20262,338.90 INR
4/13/20262,315.10 INR
4/10/20262,333.80 INR
4/9/20262,295.10 INR
4/8/20262,294.10 INR
4/7/20262,298.30 INR
4/6/20262,279.90 INR
4/2/20262,274.50 INR
4/1/20262,274.50 INR
3/30/20262,312.00 INR
3/27/20262,334.80 INR
3/25/20262,343.00 INR
3/24/20262,331.30 INR
3/23/20262,289.80 INR
3/20/20262,319.00 INR
3/19/20262,251.50 INR
3/18/20262,306.40 INR
3/17/20262,299.90 INR
3/16/20262,288.80 INR
3/13/20262,301.10 INR
3/12/20262,358.50 INR
3/11/20262,337.00 INR
3/10/20262,345.00 INR
3/9/20262,300.00 INR
3/6/20262,343.80 INR
3/5/20262,337.60 INR
2/27/20262,295.60 INR
2/26/20262,316.70 INR
2/25/20262,293.00 INR
2/23/20262,241.40 INR
2/20/20262,224.00 INR
2/19/20262,224.00 INR
2/18/20262,230.80 INR
2/17/20262,244.00 INR
2/16/20262,219.40 INR
2/13/20262,194.00 INR
2/12/20262,211.10 INR
2/11/20262,214.80 INR
2/10/20262,204.10 INR
2/9/20262,208.70 INR
2/6/20262,162.10 INR
2/5/20262,217.90 INR
2/4/20262,195.20 INR
2/3/20262,182.00 INR
2/2/20262,129.40 INR
1/30/20262,147.00 INR
1/29/20262,122.00 INR
1/28/20262,129.50 INR
1/27/20262,157.90 INR
1/23/20262,138.00 INR
1/22/20262,163.20 INR
1/21/20262,139.30 INR
1/20/20262,165.00 INR
1/19/20262,179.20 INR
1/16/20262,177.90 INR
1/14/20262,204.00 INR
1/13/20262,177.40 INR
1/12/20262,188.40 INR
1/9/20262,182.20 INR
1/8/20262,191.50 INR
1/7/20262,215.00 INR
1/6/20262,160.00 INR
1/5/20262,082.20 INR
1/2/20262,108.00 INR
1/1/20262,102.80 INR
12/31/20252,108.00 INR
12/30/20252,080.40 INR
12/29/20252,082.10 INR
12/26/20252,100.60 INR
12/24/20252,105.00 INR
12/23/20252,108.50 INR
12/22/20252,130.80 INR
12/19/20252,124.00 INR
12/18/20252,119.10 INR
12/17/20252,114.00 INR
12/16/20252,085.90 INR
12/15/20252,087.70 INR
12/12/20252,113.90 INR
12/11/20252,081.80 INR
12/10/20252,055.40 INR
12/9/20252,055.30 INR
12/8/20252,069.10 INR
12/5/20252,090.00 INR
12/4/20252,088.00 INR
12/3/20252,080.00 INR
12/2/20252,089.50 INR
12/1/20252,078.80 INR
11/28/20252,080.50 INR
11/27/20252,074.00 INR
11/26/20252,071.00 INR
11/25/20252,041.00 INR
11/24/20251,986.10 INR
11/21/20252,031.00 INR
11/20/20252,030.80 INR
11/19/20252,025.00 INR
11/18/20252,050.00 INR
11/17/20252,052.10 INR
11/14/20252,055.30 INR
11/13/20252,052.90 INR
11/12/20252,033.90 INR
11/11/20251,980.00 INR
11/10/20251,985.00 INR
11/7/20251,969.00 INR
11/6/20251,955.50 INR
11/4/20252,003.50 INR
11/3/20251,999.00 INR
10/31/20251,970.00 INR
10/30/20251,944.00 INR
10/29/20251,956.20 INR
10/28/20251,932.20 INR
10/27/20251,920.00 INR
10/24/20251,931.20 INR
10/23/20251,945.00 INR
10/21/20251,942.30 INR
10/20/20251,942.10 INR
10/17/20251,936.60 INR
10/16/20251,950.60 INR
10/15/20251,940.50 INR
10/14/20251,935.10 INR
10/13/20251,965.10 INR
10/10/20251,959.30 INR
10/9/20251,955.00 INR
10/8/20251,902.80 INR
10/7/20251,923.00 INR
10/6/20251,940.00 INR
10/3/20251,973.60 INR
10/1/20251,979.20 INR
9/30/20251,915.00 INR
9/29/20251,933.20 INR
9/26/20251,919.80 INR
9/25/20251,963.50 INR
9/24/20251,990.90 INR
9/23/20252,008.20 INR
9/22/20252,013.40 INR
9/19/20252,055.60 INR
9/18/20252,047.20 INR
9/17/20252,031.20 INR
9/16/20252,052.00 INR
9/15/20252,046.00 INR
9/12/20252,043.40 INR
9/11/20251,988.00 INR
9/10/20251,982.00 INR
9/9/20251,961.90 INR
9/8/20251,947.20 INR
9/5/20251,943.90 INR
9/4/20251,940.00 INR
9/3/20251,951.10 INR
9/2/20251,891.50 INR
9/1/20251,898.00 INR
8/29/20251,899.80 INR
8/28/20251,902.40 INR
8/26/20251,932.00 INR
8/25/20251,962.50 INR
8/22/20251,971.00 INR
8/21/20251,962.50 INR
8/20/20251,940.30 INR
8/19/20251,968.60 INR
8/18/20251,972.00 INR
8/14/20251,960.40 INR
8/13/20251,989.80 INR
Access this data via the Eulerpool API
Get Free API Key

Lupin Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
164.05 B INR
13.25 B INR
-15.28 B INR
Jan 1, 2023
166.42 B INR
9.21 B INR
4.30 B INR
Jan 1, 2024
200.11 B INR
28.09 B INR
19.14 B INR
Jan 1, 2025
227.08 B INR
42.17 B INR
32.82 B INR
Jan 1, 2026 (e)
271.26 B INR
38.58 B INR
50.26 B INR
Jan 1, 2027 (e)
298.50 B INR
42.45 B INR
45.88 B INR
Jan 1, 2028 (e)
313.40 B INR
44.57 B INR
47.34 B INR
Jan 1, 2029 (e)
344.53 B INR
49.00 B INR
54.90 B INR

Lupin Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 12, 2026, 3:42 PM
 
REVENUEB INR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB INR
EBITB INR
EBIT MARGIN%
NET INCOMEB INR
NET INCOME GROWTH%
DIV.INR
DIV. GROWTH%
SHARESM
2014201520162017201820192020202120222023202420252026e2027e2028e2029e
112.87127.70142.56174.94158.04146.65153.75151.63164.06166.42200.11227.08271.26298.50313.40344.53
17.0713.1411.6322.72-9.66-7.214.84-1.388.191.4420.2413.4819.4610.044.999.93
63.7164.5966.2667.9763.6363.2961.3061.0554.3753.7161.8465.1665.1665.1665.1665.16
71.9182.4894.46118.91100.5692.8194.2592.5889.1989.39123.76147.96176.75194.50204.21224.49
28.4533.1332.3835.9920.6517.2514.1216.9113.259.2128.0942.1738.5842.4544.5749.00
25.2125.9422.7220.5713.0611.769.1811.158.075.5314.0418.5714.2214.2214.2214.22
18.3624.0322.6125.582.516.07-2.6912.17-15.284.3019.1432.8250.2645.8847.3454.90
39.7430.86-5.9313.13-90.17141.38-144.41-551.56-225.61-128.14345.2171.4253.15-8.713.1715.97
6.006.007.507.505.005.006.006.504.004.008.0012.0012.0013.7815.83–
50.00–25.00–-33.33–20.008.33-38.46–100.0050.00–14.8314.88–
450.00452.00453.00453.00453.00454.00453.00455.24454.04456.95457.23457.77457.77457.77457.77457.77
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Lupin generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Lupin retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Lupin's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Lupin has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Lupin's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Lupin stock margins

The Lupin margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Lupin. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Lupin.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
61.06 %
11.15 %
8.02 %
Jan 1, 2022
54.37 %
8.07 %
-9.31 %
Jan 1, 2023
53.71 %
5.53 %
2.58 %
Jan 1, 2024
61.84 %
14.04 %
9.57 %
Jan 1, 2025
65.16 %
18.57 %
14.45 %
Jan 1, 2026 (e)
65.16 %
14.22 %
18.53 %
Jan 1, 2027 (e)
65.16 %
14.22 %
15.37 %
Jan 1, 2028 (e)
65.16 %
14.22 %
15.10 %

Lupin Stock Revenue, EBIT, Earnings per Share

The Lupin earnings per share therefore indicates how much revenue Lupin has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
333.08 INR
37.14 INR
26.72 INR
Jan 1, 2022
361.32 INR
29.17 INR
-33.65 INR
Jan 1, 2023
364.19 INR
20.16 INR
9.41 INR
Jan 1, 2024
437.66 INR
61.44 INR
41.87 INR
Jan 1, 2025
496.05 INR
92.12 INR
71.69 INR
Jan 1, 2026 (e)
593.61 INR
84.28 INR
109.98 INR
Jan 1, 2027 (e)
653.21 INR
92.74 INR
100.40 INR
Jan 1, 2028 (e)
685.81 INR
97.37 INR
103.59 INR

Lupin business model & stock analysis

Lupin Limited is an Indian pharmaceutical company specializing in generics and novel therapies. It was founded in 1968 by Dr. Desh Bandhu Gupta and has experienced rapid growth, becoming one of the leading companies in the global pharmaceutical market. The company's business model involves manufacturing and marketing generics and novel therapies for the treatment of various diseases such as cancer, diabetes, cardiovascular diseases, and respiratory diseases. Lupin operates worldwide with a wide range of partners to distribute its products in over 100 countries. The company is involved in various divisions including generics, novel therapies, biosimilars, and inhalation products. Lupin's generics division encompasses a wide range of products such as antibiotics, antidepressants, antihypertensives, and many other categories. Its novel therapies include innovative products for the treatment of diabetes, cancer, multiple sclerosis, and other chronic diseases. Lupin is also involved in the development of biosimilars, which are imitation biopharmaceuticals manufactured using living organisms. Lastly, the company offers inhalation products for the treatment of respiratory diseases such as asthma and COPD. Lupin has built an impressive product pipeline over the years, having submitted over 174 ANDA applications (for the approval of new generics) to the US FDA and introduced more than 80 new products in the Indian market. It has also established an innovative research and development center that focuses on the discovery of new molecules and the development of new therapeutic approaches. Another important feature of Lupin is its commitment to quality and sustainability. The company has received numerous awards for its product quality and environmental initiatives. In 2019, Lupin received the Sustainable Business Award from CNBC TV18. Overall, Lupin Limited is a successful and fast-growing company specializing in generics and novel therapies. It has a wide range of products and an impressive pipeline, and operates globally. Due to its commitment to quality and sustainability, Lupin Limited has also built a strong reputation among its customers and partners.

Lupin SWOT Analysis

Strengths

Strong brand recognition: Lupin Ltd has established a strong brand presence in the pharmaceutical industry, known for its quality products and innovation.

Diversified product portfolio: The company offers a wide range of pharmaceutical products across various therapeutic areas, reducing dependency on any single product.

Global presence: Lupin Ltd has a strong international presence, with operations in several countries, allowing it to tap into diverse markets and customer segments.

Weaknesses

Dependency on few key markets: While Lupin Ltd has global operations, it heavily relies on a few key markets for significant revenue, which poses a risk in case of market fluctuations or regulatory challenges in those regions.

Limited pipeline of new drugs: The company's pipeline of new drugs under development is relatively limited, which could impact its ability to maintain a competitive edge and drive future growth.

Increasing competition: Lupin Ltd faces intense competition from other pharmaceutical companies, both domestic and international, which may impact its market share and pricing power.

Opportunities

Rising demand for generic drugs: The increasing preference for affordable healthcare and patent expirations in the pharmaceutical industry present an opportunity for Lupin Ltd to expand its generic drug offerings.

Emerging markets: Developing economies are experiencing a surge in healthcare spending, providing Lupin Ltd with growth opportunities in untapped markets.

Innovation and research: Investing in research and development capabilities can help Lupin Ltd develop new drugs and therapies, driving future growth and differentiation.

Threats

Stringent regulatory environment: Compliance with evolving regulations and increasing scrutiny in the pharmaceutical industry poses a threat to Lupin Ltd's operations and profitability.

Patent expirations: The expiration of patents for key drugs may lead to increased competition from generic drug manufacturers, resulting in reduced market share and lower profitability.

Currency exchange risks: As a global company, Lupin Ltd is exposed to currency exchange rate fluctuations, which can impact its financial performance and profitability.

Lupin Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Lupin historical P/E ratio, EBIT multiple, and P/S ratio

Lupin annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Lupin shares outstanding

The number of shares of Lupin was 457.77 M in 2025. This indicates how many shares Lupin is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
455.24 M Stocks
Jan 1, 2022
454.04 M Stocks
Jan 1, 2023
456.95 M Stocks
Jan 1, 2024
457.23 M Stocks
Jan 1, 2025
457.77 M Stocks
Jan 1, 2026 (e)
457.77 M Stocks
Jan 1, 2027 (e)
457.77 M Stocks
Jan 1, 2028 (e)
457.77 M Stocks

Lupin stock splits

In Lupin's history, there have been no stock splits.

Lupin Dividend History

28 years of dividend payments · 2 consecutive increases

YearAnnual DividendYoY ChangePayments
202512.00INR↑ 50.0%1×
Jul 25, 202512.00INR↑ 50.0%1/1
20248.00INR↑ 100.0%1×
20234.00INR 0.0%1×
20224.00INR↓ 38.5%1×
20216.50INR↑ 8.3%1×
20206.00INR↑ 20.0%1×
20195.00INR 0.0%1×
20185.00INR↓ 33.3%1×
20177.50INR 0.0%1×
20167.50INR 0.0%1×

Lupin dividend history and estimates

In 2025, Lupin paid a dividend amounting to 12.00 INR. Dividend means that Lupin distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
6.50 INR
0.00 INR
Jan 1, 2022
4.00 INR
0.00 INR
Jan 1, 2023
4.00 INR
0.00 INR
Jan 1, 2024
8.00 INR
0.00 INR
Jan 1, 2025
12.00 INR
0.00 INR
Jan 1, 2026
12.00 INR
0.00 INR
Jan 1, 2027 (e)
0.00 INR
13.78 INR
Jan 1, 2028 (e)
0.00 INR
15.83 INR

Lupin dividend payout ratio

In 2025, Lupin had a payout ratio of 16.74%. The payout ratio indicates the percentage of the company's profits that Lupin distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
24.32 %
Jan 1, 2022
-11.89 %
Jan 1, 2023
42.50 %
Jan 1, 2024
19.11 %
Jan 1, 2025
16.74 %
Jan 1, 2026 (e)
10.91 %
Jan 1, 2027 (e)
13.73 %
Jan 1, 2028 (e)
15.29 %

Current Lupin forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
67.44 % (29)
Hold
25.58 % (11)
Sell
6.98 % (3)
12M Price Target
2,397.00
Last Price
2,278.90
Currency
INR
12M Return Potential
5.18 %
LTM Return
0 %

Lupin Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
5/7/20249.73INR-48.68 BINR-2024 Q4
2/7/20248.65INR-49.30 BINR-2024 Q3

EESG©

Eulerpool ESG Scorecard© for the Lupin stock

77/100
72
Environment
92
Social
68
Governance
E

Environment

20
Scope 1 - Direct Emissions86,345
Scope 2 - Indirect emissions from purchased energy306,503
Scope 3 - Indirect emissions within the value chain1,119,125
Total CO₂ emissions392,848
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees9
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Lupin shareholder structure

% Name
45.34092%
Lupin Investments Pvt. Ltd.
Lupin Investments Pvt. Ltd.
4.33335%
HDFC Asset Management Co., Ltd.
HDFC Asset Management Co., Ltd.
2.09463%
Nippon Life India Asset Management Limited
Nippon Life India Asset Management Limited
1.73832%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.72033%
SBI Funds Management Pvt. Ltd.
SBI Funds Management Pvt. Ltd.
1.51825%
Mirae Asset Global Investments (India) Pvt. Ltd.
Mirae Asset Global Investments (India) Pvt. Ltd.
...

Lupin Beneficial Ownership Filings (SEC 13D/G)

Free Float
53.0%
Float Shares
-
Shares Outstanding
-

Lupin Executives and Management Board

27 members · avg. age 63 · 15 % women

VG

Ms. Vinita Gupta (56)

Chief Executive Officer, Executive Director

235.59 M INR

Management

NG

Mr. Nilesh Gupta (50)

Managing Director, Executive Director

95.78 M INR
RS

Mr. Ramesh Swaminathan (57)

Executive Director, Global Chief Financial Officer, Chief Risk Officer and Head of API Plus SBU · since 2007

81.69 M INR
NG

Mr. Naresh Gupta

President - API Plus and Global TB

14.43 M INR
RC

Mr. Rajendra Chunodkar

President - Manufacturing Operations

–
FE

Dr. Fabrice Egros

President - Corporate Development and Growth Markets · since 2021

–
SG

Mr. Spiro Gavaris

President - U.S. Generics

–

Board of Directors

KA

Mr. K. B. S. Anand (66)

Non-Executive Independent Director

15.59 M INR
MM

Mr. Mark Mcdade (67)

Non-Executive Independent Director

15.52 M INR
JB

Mr. Jean-Luc Belingard (73)

Non-Executive Independent Director

15.46 M INR
MG

Mrs. Manju Gupta (78)

Non-Executive Chairman of the Board · since 2011

8.87 M INR
PK

Dr. Punita Kumar-Sinha (60)

Non-Executive Independent Director

1.65 M INR
JK

Mr. Jeffrey Kindler (68)

Non-Executive Independent Director

–

Frequently asked questions about Lupin

The business model of Lupin Ltd revolves around the pharmaceutical industry. As a leading global pharmaceutical company, Lupin focuses on developing, manufacturing, and marketing a diverse range of generic and branded pharmaceutical products. With a strong emphasis on research and development, Lupin strives to bring innovative solutions and affordable medications to patients worldwide. The company's business model includes a global presence, strategic partnerships, and a commitment to quality and compliance. Lupin Ltd's extensive product portfolio covers various therapeutic areas, including cardiovascular, central nervous system, dermatology, and respiratory, among others, catering to the healthcare needs of millions of people.

Lupin Ltd is primarily active in the pharmaceutical industry.

The main competitors of Lupin Ltd in the market include companies like Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Cipla Ltd., and Torrent Pharmaceuticals Ltd.

Lupin Ltd. is a renowned pharmaceutical company with a rich history and background. Established in 1968, Lupin has emerged as a global leader in the pharmaceutical industry. The company's relentless focus on innovation and research has paved the way for groundbreaking drug discoveries and cutting-edge formulations. Lupin operates through various business segments, catering to a wide range of therapeutic areas including cardiovascular, respiratory, central nervous system, and anti-infective. With a strong global presence across multiple countries, Lupin has earned a stellar reputation for delivering affordable and high-quality healthcare solutions. Over the years, Lupin Ltd. has consistently showcased its commitment to improving global health outcomes with its diverse portfolio of pharmaceutical products.

Lupin Ltd has accomplished several significant milestones throughout its history. One of the major achievements was the company's successful listing on the Bombay Stock Exchange and the National Stock Exchange of India. Lupin also made notable achievements in the global pharmaceutical industry by receiving various regulatory approvals for its high-quality and affordable generic medications. Furthermore, Lupin has expanded its operations globally by establishing a strong presence in key markets like the United States, Europe, Japan, and other emerging markets. These achievements have reinforced Lupin's position as a leading global pharmaceutical company, delivering innovative healthcare solutions to patients worldwide.

Lupin Ltd, a renowned pharmaceutical company, has a significant global presence. The company primarily operates in various countries and regions, including but not limited to India, United States, Europe, Japan, and South Africa. With its strong foothold in these markets, Lupin Ltd has established itself as a leading player in the pharmaceutical industry.

Lupin Ltd is known for upholding strong values and a robust corporate philosophy. Guided by their core principles, Lupin strives for excellence, integrity, and transparency in all their operations. The company firmly believes in providing high-quality pharmaceutical products that improve the lives of patients globally. With a focus on innovation, Lupin continually invests in research and development to bring cutting-edge healthcare solutions to the market. Dedicated to social responsibility, Lupin actively engages in initiatives for the betterment of society, promoting sustainable development and fostering inclusive growth. Through their unwavering commitment to quality, ethics, and social welfare, Lupin Ltd emerges as an industry leader, delivering value to various stakeholders and ensuring a positive impact on the healthcare sector.

Analysts currently set an average price target of 2,338.63 INR for the Lupin stock (median: 2,397.00 INR), implying +2.6 % versus the latest price. The consensus is based on 43 analyst ratings.

Lupin Analyst Price Targets 2026

43 analysts currently rate the Lupin stock: 29 recommend buying, 11 holding and 3 selling. For 2026, analysts expect Lupin to generate revenue of 271.26 B INR and earnings per share of 109.79 INR.

Lupin Analyst Price Targets 2026

Converted at the current exchange rate, the Lupin share trades at 20.88 EUR (2,300.00 INR).

Lupin Ltd is a leading pharmaceutical company based in India. The company's business model is based on the production and distribution of pharmaceutical products and generic medications worldwide. Lupin operates in three business segments: generics, branded products, and carbamazepine. The generics segment is the core of Lupin's business model, offering a wide range of cost-effective alternatives to expensive brand-name medications. Lupin also produces branded products, primarily sold in India, including antibiotics, diabetes medications, and hormonal treatments. The carbamazepine segment specializes in the production of antiepileptic drugs and is a significant part of Lupin's business model. The company also emphasizes research and development, investing a significant percentage of its revenue in the development of new drugs. Lupin has established a global distribution network, with subsidiaries in the US, Europe, and Japan, as well as distribution partners in other countries. The company has made strategic acquisitions and mergers to strengthen its presence in different regions, such as the acquisition of Gavis in 2016 to expand its generics business in the US. Overall, Lupin's business model revolves around the production and distribution of pharmaceutical products and generics worldwide, with a strong emphasis on research and development and a global distribution network.

The expected revenue of Lupin is 271.26 B INR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Lupin is 50.26 B INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Lupin is currently 20.95. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Lupin stock.

The price-to-sales ratio (P/S) of Lupin is currently 3.88. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Lupin stock.

The Eulerpool Quality Score for Lupin is 4/10.

The ISIN of Lupin is INE326A01037. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Lupin is LUPIN.NS. The ticker symbol is used to trade Lupin shares on the stock exchange.

Over the past 12 months, Lupin paid a dividend of 12.00 INR . This corresponds to a dividend yield of about 0.52 %. For the coming 12 months, Lupin is expected to pay a dividend of 13.78 INR.

The current dividend yield of Lupin is 0.52 %.

Lupin pays a dividend, distributed in the months of , , , .

Lupin paid dividends every year for the past 28 years.

For the upcoming 12 months, dividends amounting to 13.78 INR are expected. This corresponds to a dividend yield of 0.60 %.

Lupin is assigned to the 'Health' sector.

To receive the latest dividend of Lupin from amounting to 12 INR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Lupin distributed 4 INR as dividends.

The dividends of Lupin are distributed in INR.

All fundamentals and in-depth analysis of Lupin

Our stock analysis for Lupin stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lupin. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Lupin Stock
Lupin Revenue→
Lupin Stock
Lupin Net Income→
Lupin Stock
Lupin P/E→
Lupin Stock
Lupin P/S→
Lupin Stock
Lupin EBIT→
Lupin Stock
Lupin Dividend→
Lupin Stock
Lupin Directors Dealings→
Lupin Stock
Lupin Stocks→
Lupin Stock
Lupin Market capitalization→
Lupin Stock
Lupin Debt→
Lupin Stock
Lupin Liabilities→
Lupin Stock
Lupin Equity→
Lupin Stock
Lupin AAQS→
Lupin Stock
Lupin Employees→
Lupin Stock
Lupin ROE→
Lupin Stock
Lupin ROA→
Lupin Stock
Lupin ROCE→
Lupin Stock
Lupin News→
Lupin Stock
Lupin Analyst Price Targets→

Health Stocks

LuxbrightLuoxin Pharmaceuticals Group Stock CoLuyan Pharma CoLunitLuye Pharma GroupLunai BioworksLyell ImmunopharmaLumosa Therapeutics CoLyka LabsLuminexLyra TherapeuticsLumexa Imaging HoldingsAll Stocks A–Z →